Voorschriften van de geneesheren specialisten in de gastro-enterologie (kwal. 65 + 650) (1,08% van de voorschrijvers)
Ambulante sector - Jaar 2025

# Totaal per ATC-klasse 1ste niveau

| ATC 1ste niveau | Anatomisch niveau | Brutobedrag (duizenden EURO) | % | % in het brutobedrag van alle voorschrijvers | Persoonlijk aandeel (duizenden EURO) | % | DDD/1000 inw./dag | % |
|---|---|---|---|---|---|---|---|---|
| A | MAAGDARMKANAAL EN STOFWISSELING | 12,898 | 8.0% | 2.1% | 2,719 | 61.5% | 4.470 | 48.7% |
| B | BLOED EN BLOEDVORMENDE ORGANEN | 713 | 0.4% | 0.2% | 76 | 1.7% | 0.212 | 2.3% |
| C | HARTVAATSTELSEL | 1,323 | 0.8% | 0.2% | 241 | 5.5% | 0.998 | 10.9% |
| D | DERMATOLOGISCHE PREPARATEN | 512 | 0.3% | 0.5% | 11 | 0.3% | 0.012 | 0.1% |
| G | UROGENITAAL STELSEL EN GESLACHTSHORMONEN | 17 | 0.0% | 0.1% | 4 | 0.1% | 0.014 | 0.1% |
| H | SYSTEMISCHE HORMOONPREP., GESLACHTSHORMONEN UITGEZ. | 2,311 | 1.4% | 2.3% | 42 | 0.9% | 0.180 | 2.0% |
| J | ANTIMICROBIELE MIDDELEN VOOR SYSTEMISCH GEBRUIK | 5,291 | 3.3% | 1.4% | 217 | 4.9% | 0.257 | 2.8% |
| L | CYTOSTATICA EN IMMUNOMODULERENDE MIDDELEN | 136,999 | 85.0% | 18.3% | 912 | 20.6% | 2.531 | 27.6% |
| M | SKELETSPIERSTELSEL | 133 | 0.1% | 0.1% | 13 | 0.3% | 0.075 | 0.8% |
| N | ZENUWSTELSEL | 555 | 0.3% | 0.1% | 95 | 2.1% | 0.203 | 2.2% |
| P | ANTIPARASITAIRE MIDDELEN | 80 | 0.0% | 1.7% | 8 | 0.2% | 0.012 | 0.1% |
| R | ADEMHALINGSSTELSEL | 318 | 0.2% | 0.1% | 78 | 1.8% | 0.204 | 2.2% |
| S | ZINTUIGLIJKE ORGANEN | 17 | 0.0% | 0.0% | 3 | 0.1% | 0.011 | 0.1% |
| V | DIVERSE MIDDELEN | 38 | 0.0% | 0.2% | 1 | 0.0% | 0.001 | 0.0% |
| TOTAAL | | 161,207 | 100.0% | 3.8% | 4,420 | 100.0% | 9.181 | 100.0% |

Voorschriften van de geneesheren specialisten in de gastro-enterologie (kwal. 65 + 650) (1,08% van de voorschrijvers)
Ambulante sector - Jaar 2025

## DU 90%

| Plaats (bedrag) | ATC code | Chemische ondergroep | % bruto-bedrag | Brutobedrag (duizenden EURO) | % van het brutobedrag van alle geneesheren | Aantal DDD (duiz.) | % DDD | Plaats (DDD) |
|---|---|---|---|---|---|---|---|---|
| 1 | L04AC | INTERLEUKINEREMMERS | 27.1% | 43,717 | 17.7% | 4,763 | 12.0% | 2 |
| 2 | L04AB | TUMORNECROSEFACTOR-ALFA (TNF-ALFA) REMMERS | 27.0% | 43,523 | 23.4% | 3,262 | 8.2% | 4 |
| 3 | L04AG | MONOKLONALE ANTILICHAMEN | 17.2% | 27,702 | 44.8% | 1,193 | 3.0% | 5 |
| 4 | L04AF | JANUS-KINASE (JAK)-INHIBITOREN | 11.3% | 18,261 | 23.4% | 912 | 2.3% | 9 |
| 5 | A02BC | INHIBITOREN VAN DE PROTONPOMP | 2.4% | 3,791 | 2.7% | 11,234 | 28.3% | 1 |
| 6 | A07EC | MESALAZINE EN VERWANTE VERBINDINGEN | 2.3% | 3,716 | 31.8% | 3,733 | 9.4% | 3 |
| 7 | J05AF | NUCLEOSIDE EN NUCLEOTIDE REVERSE TRANSCRIPTASEREMMERS | 2.3% | 3,653 | 65.5% | 679 | 1.7% | 10 |
| 8 | H01CB | SOMATOSTATINE EN ANALOGEN | 1.3% | 2,158 | 7.0% | 96 | 0.2% | 41 |
| TOTAAL | | | 90.9% | 146,522 | - | 25,873 | 65.3% | - |

Voorschriften van de geneesheren specialisten in de gastro-enterologie (kwal. 65 + 650) (1,08% van de voorschrijvers)
Ambulante sector - Jaar 2025

## Detaille per werkzaam bestanddeel van de 20 chemische ondergroepen met de grootste brutobedragen

| Plaats in de DU 90% | ATC 4de niveau | ATC 5de niveau | Werkzaam bestanddeel | Bruto-bedrag (duiz. EURO) | % van het brutobedrag van alle geneesheren | Aantal DDD (duiz.) |
|---|---|---|---|---|---|---|
| 1 | L04AC | L04AC05 | USTEKINUMAB | 24,176 | 68.4% | 2,867.0 |
| | | L04AC18 | RISANKIZUMAB | 17,089 | 30.0% | 1,824.0 |
| | | L04AC24 | MIRIKIZUMAB | 2,449 | 89.7% | 72.2 |
| | | L04AC14 | SARILUMAB | 3 | 0.0% | 0.1 |
| 2 | L04AB | L04AB04 | ADALIMUMAB | 25,831 | 28.2% | 1,577.4 |
| | | L04AB02 | INFLIXIMAB | 16,695 | 77.9% | 1,633.9 |
| | | L04AB06 | GOLIMUMAB | 997 | 4.3% | 50.6 |
| 3 | L04AG | L04AG05 | VEDOLIZUMAB | 27,700 | 86.9% | 1,193.5 |
| | | L04AG12 | OFATUMUMAB | 2 | 0.0% | 0.0 |
| 4 | L04AF | L04AF03 | UPADACITINIB | 15,390 | 37.8% | 803.8 |
| | | L04AF04 | FILGOTINIB | 1,573 | 12.3% | 55.2 |
| | | L04AF01 | TOFACITINIB | 1,298 | 13.7% | 53.5 |
| 5 | A02BC | A02BC02 | PANTOPRAZOL | 2,169 | 2.4% | 6,145.8 |
| | | A02BC05 | ESOMEPRAZOL | 1,048 | 6.0% | 3,195.4 |
| | | A02BC01 | OMEPRAZOL | 499 | 1.6% | 1,706.0 |
| | | A02BC03 | LANSOPRAZOL | 69 | 4.4% | 175.5 |
| | | A02BC04 | RABEPRAZOL | 5 | 4.0% | 11.3 |
| 6 | A07EC | A07EC02 | MESALAZINE | 3,697 | 34.1% | 3,687.2 |
| | | A07EC01 | SULFASALAZINE | 19 | 2.3% | 45.8 |
| 7 | J05AF | J05AF07 | TENOFOVIR DISOPROXIL | 1,908 | 67.2% | 423.9 |
| | | J05AF13 | TENOFOVIR ALAFENAMIDE | 1,023 | 68.9% | 105.1 |
| | | J05AF10 | ENTECAVIR | 700 | 64.0% | 141.3 |
| | | J05AF05 | LAMIVUDINE | 22 | 18.0% | 8.4 |
| 8 | H01CB | H01CB03 | LANREOTIDE | 1,270 | 6.8% | 47.9 |
| | | H01CB02 | OCTREOTIDE | 888 | 8.2% | 48.5 |